Amyotrophic lateral sclerosis (ALS) is a late-onset fatal neurodegenerative disease affecting motor neurons with an incidence of about 1/100,000. Most ALS cases are sporadic, but 5–10% of the cases are familial ALS. Both sporadic (SALS) and familial ALS (FALS) are associated with degeneration of cortical and spinal motor neurons.(1) The causes of amyotrophic lateral sclerosis are only partly known, but they include some environmental risk factors as well as several genes that have been identified as harbouring disease-associated variation.(2) Genetic studies have implicated deficits in autophagy and/or mitophagy in the onset of the disease.(3) So far, there is no breakthrough for the treatment of ALS. The main treatments are neuroprotective treatment, symptomatic and supportive treatment as well as some unproven disease-modifying therapies such as stem cell transplantation and gene therapy.(4)
Recombinant monoclonal antibodies for ALS disease research
We support your ALS research with reliable, recombinant monoclonal antibodies with high batch-to-batch consistency. Below you will find some of our most referenced or bestselling products.